Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for testing for cardiovascular disease with cyclophilin A

a cardiovascular disease and cyclophilin technology, applied in the field of cardiovascular disease examination methods, can solve the problems of increasing medical costs, patient death, and burden on both the subject to be examined and the healthcare professional, and achieve the effects of easy selection of treatment, high accuracy, and easy examination of cardiovascular diseas

Active Publication Date: 2017-10-17
TOHOKU UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a novel examination method for cardiovascular disease with high accuracy. The method can distinguish patients who require more thorough examinations or appropriate treatments. This makes it easier to select a suitable treatment for an individual patient suspected of having cardiovascular disease.

Problems solved by technology

When the cardiovascular disease becomes severe, the patient may die.
However, only a small percentage of patients with chest pain or the like actually develop or have a probability of development of the cardiovascular disease.
However, it is necessary to insert a catheter into the vessel in the cardiac catheterization and to introduce a contrast dye into the vessel in the angiography, resulting in heavy burdens on both a subject to be examined and a healthcare professional.
Further, cost burdens for the examination may increase medical costs spent by the country or the like.
Therefore, it is difficult to conduct a thorough examination for all patients with subjective symptoms.
However, the differential diagnosis based on the history taking is insufficient in accuracy because of its large dependence on experiences of doctors.
However, it is difficult to examine the presence or absence of a non-severe cardiovascular disease with troponin T. In addition, high-sensitivity CRP is non-specific because the high-sensitivity CRP level increases in patients with various inflammatory diseases.
Therefore, high-sensitivity CRP is not a reliable biomarker that is used in routine differential diagnosis for a cardiovascular disease even at the present day when measurement environments are sufficient.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for testing for cardiovascular disease with cyclophilin A
  • Method for testing for cardiovascular disease with cyclophilin A
  • Method for testing for cardiovascular disease with cyclophilin A

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0098]The correlation between coronary artery disease and the concentration of cyclophilin A protein in plasma was examined.

[0099]1. Method

[0100]Patient Groups

[0101]A prospective observational study of the prognostic value of CyPA was conducted in patients with symptoms or signs of coronary artery disease (CAD) who were referred to the Tohoku University Hospital (Sendai) for selective coronary angiography (CAG) from November 2007 through October 2011. It should be noted that, if patients underwent angiography more than once, an analysis was based only on data obtained at the time of the first angiographic study. Patients with valvular or congenital heart disease and patients with unstable angina or myocardial infarction were excluded. 320 patients who had angina pectoris and signs of ischemia on exercise electrocardiogram or myocardial radionuclide imaging were enrolled. The Ethical Review Board approved the study, and written informed consent was given by all participating patients...

example 2

[0136]A correlation among aortic aneurysm and the concentration of cyclophilin A protein in plasma was examined.

[0137]1. Method

[0138]Patient Groups

[0139]Among the patients examined in Example 1, patients determined to have thoracic aortic aneurysm or abdominal aortic aneurysm by diagnostic imaging were classified into a group of patients with aortic aneurysm (N=60). Among the patients examined in Example 1, patients determined to have no thoracic aortic aneurysm and no abdominal aortic aneurysm were classified into a control group (N=69).

[0140]Statistical Analysis

[0141]A statistical analysis was conducted according to the method described in Example 1.

[0142]2. Results and Discussion

[0143]FIG. 9 show correlations between CyPA level and the presence or absence of aortic aneurysm that can be discriminated by diagnostic imaging such as CT. The CyPA level was significantly higher in the patients with aortic aneurysm (p<0.001). The CyPA level tended to be particularly higher in the patien...

example 3

[0145]A correlation among pulmonary hypertension and the concentration of cyclophilin A protein in plasma was examined.

[0146]1. Method

[0147]Patient Groups

[0148]This study was conducted using plasma samples obtained from patients with pulmonary hypertension (N=130) and control patients (N=25) in right heart catheterization, which was conducted at the Tohoku University Hospital (Sendai) from 2008 through 2011. The control patients are ones who were suspected to have pulmonary hypertension in echocardiography but were found to have no pulmonary hypertension in right heart catheterization (mean pulmonary artery pressure (mPAP)<25 mmHg).

[0149]Baseline Measurement and Statistical Analysis

[0150]Baseline Measurement and a statistical analysis were conducted according to the methods described in Example 1.

[0151]2. Results and Discussion

[0152]FIG. 11 shows a correlation between CyPA level and the presence or absence of pulmonary hypertension. The CyPA level was significantly higher in the pat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to provide a novel examination method for a cardiovascular disease. As means for achieving the object, provided is an examination method for a cardiovascular disease, the method including the steps of: measuring a concentration of cyclophilin A protein in a human blood sample; and determining a probability of development of a cardiovascular disease based on the measured concentration of cyclophilin A protein.

Description

TECHNICAL FIELD[0001]The present invention primarily relates to an examination method for a cardiovascular disease. The present invention also relates to an examination kit for a cardiovascular disease and a treatment method for a cardiovascular disease.BACKGROUND ART[0002]Arteriosclerosis, which is induced and progressed by various risk factors, causes thickening of the arterial lumen to interrupt blood flow, resulting in a cardiovascular disease such as aortic aneurysm, angina, myocardial infarction, or cerebral infarction. When the cardiovascular disease becomes severe, the patient may die. Therefore, the patient is desirably subjected to early diagnosis and appropriate treatments. One of the subjective symptoms of patients with the cardiovascular disease is chest pain or discomfort. However, only a small percentage of patients with chest pain or the like actually develop or have a probability of development of the cardiovascular disease. Therefore, the patients are required to b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/99G01N2800/32
Inventor SHIMOKAWA, HIROAKISATOH, KIMIO
Owner TOHOKU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com